Maxim Group

Maxim Group reiterated its Sell rating and $80.00 price target on Baidu (NASDAQ: BIDU) following Q4 results. Maxim Group commented, "During the quarter, BIDU was able to grow the number of advertisers by 30.5% y/y (4.1% q/q) at the expense of revenue per advertiser, which grew 7.6% y/y but...

Maxim Group downgraded Cree (NASDAQ: CREE) from Buy to Hold and removed the price target of $40.00. Maxim Group commented, "Driven less by fundamentals than valuation, we downgrade CREE to Hold, from Buy, as we believe the stock's sudden surge YTD now reflects the bulk of the potential upside we...

In a report published Monday, Maxim Group downgraded its rating on Youku Tudou (NYSE: YOKU) from Hold to Sell, and named a $16.00 price target. Maxim Group noted, “We are downgrading YOKU to Sell, from Hold, mainly due to likely lower-than-expected profitability in the coming years. YOKU is...

In a report published Monday, Maxim Group reiterated its Buy rating on Qihoo 360 Technology Co. Ltd. (NYSE: QIHU), and raised its price target from $28.00 to $37.00. Maxim Group noted, “Search has started to generate ad dollars. QIHU's stock has appreciated more than 30% since reporting 3Q12...

Maxim Group initiated coverage on Baidu (NASDAQ: BIDU) with a Sell rating and a $80 price target. Maxim Group commented, "With 80% revenue and 72% traffic shares in 3Q12, as well as stellar growth and margin expansion since its IPO in 2005, we believe the operations of China's dominant search...

Maxim Group reiterated its Buy rating on ARIAD Pharmaceuticals (NASDAQ: ARIA) and a $24 price target. Maxim Group said, "Unexpectedly, Iclusig's label contains a boxed warning on arterial thrombosis and hepatotoxicity. … The information suggests (1) Iclusig may have an disadvantage in competing...

In a report published Friday, Maxim Group reiterated its Buy rating and $50.00 price target on Tesla Motors (NASDAQ: TSLA). Maxim Group noted, “Though not yet official, recent TSLA commentary suggests an increase in the Model S price for new reservations is on the horizon. Though this may lead to...

In a report published Wednesday, Maxim Group reiterated its Buy rating on China Gerui Advanced Materials (NASDAQ: CHOP), but slightly lowered its price target from $5.00 to $4.00. Maxim Group noted, “Even with the new term of government in position, we do not expect drastic stimulus plans in the...

In a report published Wednesday, Maxim Group reiterated its Buy rating and $38.00 price target on Cree (NASDAQ: CREE). Maxim Group noted, “With a better-than-expected rebound in gross margin driving FY1Q13 upside and guidance for ~5% Q/Q revenue growth and margin gains in FY2Q13, we expect CREE to...

In a report published Monday, Maxim Group reiterated its Buy rating and $28.00 price target on Ariad Pharmaceuticals (NASDAQ: ARIA). Maxim Group noted, “This morning ARIA hosted a conference call further explaining the phase I data (of an ongoing phase I/II trial) of AP26113 in NSCLC (non-small...

In a report published Monday, Maxim Group reiterated its Buy rating and $10.00 price target on Threshold Pharmaceuticals (NASDAQ: THLD). Maxim Group noted, “THLD presented detailed analyses of the phase IIb trial (404) of TH-302 in combination with gemcitabine in pancreatic cancer on Saturday,...

In a report published Friday, Maxim Group reiterated its Sell rating and $9.00 price target on First Solar (NASDAQ: FSLR). Maxim Group noted, “Triggered by a double dose of misguided optimism—first over a new project win and second speculation of a new one—FSLR's stock popped 11% Thursday, but we...

Maxim Group reduced its rating on Youku Tudou (NYSE: YOKU) from Buy to Hold and removed its previous price target of $24 per share. Maxim Group noted, "At the end of August, YOKU completed its acquisition of Tudou, once YOKU's largest competitor. As previously analyzed, we believe the combination...

In a report published Wednesday, Maxim Group reiterated its Buy rating and $50.00 price target on Tesla Motors (NASDAQ: TSLA). Maxim Group noted, “While TSLA's stock tumbled (10%) Tue. on the one-two punch of a secondary and a cut to 2012 guidance, we expect selling pressure to subside following...

Maxim Group initiated coverage on Threshold Pharmaceuticals (NASDAQ: THLD) with a Buy rating and a price target of $10 per share. Maxim Group commented, "THLD's lead drug, TH-302, is currently in a phase III trial as a first-line treatment with doxorubicin for advanced soft tissue sarcoma (STS)...